drugset

drugset / Trial / NCT04156685

Pharmacokinetics, Safety and Tolerability of CKD-387 10/500mg BE Phase1

NCT04156685 ↗

Phase 1 Completed 58 enrolled Chong Kun Dang Pharmaceutical

RandomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of CKD-387

Timeline

Start: 2019-08-06
Primary completion: 2019-08-30
Completion: 2019-10-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	D635	Unknown	—	—

Indications